Benzinga
Nektar Therapeutics Insider Trades $315K In Company Stock
Gil Labrucherie, CFO at Nektar Therapeutics (NASDAQ:NKTR), made a large insider sell on November 18, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Labrucherie sold 24,149 shares of Nektar Therapeutics at prices ranging from $12.69 to $13.16. The total transaction amounted to $316,391. Following the transaction, Labrucherie still owns 256,682 shares of Nektar Therapeutics worth $3,100,718.00. Nektar Therapeut
